In the preceding three months, 10 analysts have released ratings for Myriad Genetics (NASDAQ:MYGN), presenting a wide array of perspectives from bullish to bearish. Summarizing their recent ...

Myriad Genetics, Inc.’s MYGN Oncology growth strategy, which focuses on expanding companion diagnostics and market growth through new clinical guidelines, is poised to drive growth in the upcoming ...

Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 10.6% in the morning session after Piper Sandler analysts upgraded the stock's rating from Neutral to Buy. The improved ...

Myriad Genetics, Inc.’s MYGN Oncology growth strategy ... relevant products supported by a growing volume of clinical studies and data.